NIH #5R35CA283977-03
Targeting Pediatric Cancer Vulnerabilities
Active
- Amount
- $1.1M
- Period
- 2023-09-19 → 2030-08-31
- PIs
- 1
- Est. capacity / PI
- ~10 students
Awarded at DANA-FARBER CANCER INST
NIH #5R35CA283977-02
Targeting Pediatric Cancer Vulnerabilities
Active
- Amount
- $1.0M
- Period
- 2023-09-19 → 2030-08-31
- PIs
- 1
- Est. capacity / PI
- ~10 students
Awarded at DANA-FARBER CANCER INST
NIH #1R35CA283977-01
Targeting Pediatric Cancer Vulnerabilities
Active
- Amount
- $1.1M
- Period
- 2023-09-19 → 2030-08-31
- PIs
- 1
- Est. capacity / PI
- ~10 students
Awarded at DANA-FARBER CANCER INST
NIH #5P01CA217959-08
Targeting neuroblastoma cell state plasticity
Active
- Amount
- $622K
- Period
- 2017-09-18 → 2029-02-28
- PIs
- 1
- Est. capacity / PI
- ~2 students
Awarded at CHILDREN'S HOSP OF PHILADELPHIA
NIH #5P01CA217959-07
Targeting neuroblastoma cell state plasticity
Active
- Amount
- $408K
- Period
- 2017-09-18 → 2029-02-28
- PIs
- 1
- Est. capacity / PI
- ~1 students
Awarded at CHILDREN'S HOSP OF PHILADELPHIA
NIH #5U01CA281840-03
Immunotherapeutic targeting of gangliosides in Ewing Sarcoma
Active
- Amount
- $767K
- Period
- 2023-09-19 → 2028-08-31
- PIs
- 2
- Est. capacity / PI
- ~2 students
Awarded at DANA-FARBER CANCER INST
NIH #5U01CA281840-02
Immunotherapeutic targeting of gangliosides in Ewing Sarcoma
Active
- Amount
- $755K
- Period
- 2023-09-19 → 2028-08-31
- PIs
- 2
- Est. capacity / PI
- ~2 students
Awarded at DANA-FARBER CANCER INST
NIH #1U01CA281840-01
Immunotherapeutic targeting of gangliosides in Ewing Sarcoma
Active
- Amount
- $795K
- Period
- 2023-09-19 → 2028-08-31
- PIs
- 2
- Est. capacity / PI
- ~2 students
Awarded at DANA-FARBER CANCER INST
NIH #5R01CA283395-04
Mechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma
Active
- Amount
- $714K
- Period
- 2023-06-07 → 2028-05-31
- PIs
- 2
- Est. capacity / PI
- ~2 students
Awarded at DANA-FARBER CANCER INST
NIH #5R01CA283395-03
Mechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma
Active
- Amount
- $714K
- Period
- 2023-06-07 → 2028-05-31
- PIs
- 2
- Est. capacity / PI
- ~2 students
Awarded at DANA-FARBER CANCER INST
NIH #5R01CA283395-02
Mechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma
Active
- Amount
- $678K
- Period
- 2023-06-07 → 2028-05-31
- PIs
- 2
- Est. capacity / PI
- ~2 students
Awarded at DANA-FARBER CANCER INST
NIH #1R01CA283395-01
Mechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma
Active
- Amount
- $733K
- Period
- 2023-06-07 → 2028-05-31
- PIs
- 2
- Est. capacity / PI
- ~2 students
Awarded at DANA-FARBER CANCER INST
NIH #3OT2CA297572-01S1
PROTECT (Harnessing PROTEin degradation for Advanced Childhood Tumors)
- Amount
- $1.8M
- Period
- 2024-05-01 → 2026-04-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #1OT2CA297572-01
PROTECT (Harnessing PROTEin degradation for Advanced Childhood Tumors)
- Amount
- $1.4M
- Period
- 2024-05-01 → 2026-04-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #3U54CA231637-01S2
The Center for Therapeutic Targeting of EWS-oncoproteins
- Amount
- $505K
- Period
- 2022-09-07 → 2024-06-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #3U54CA231637-01S1
The Center for Therapeutic Targeting of EWS-oncoproteins
- Amount
- $198K
- Period
- 2021-07-01 → 2024-06-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #1U54CA231637-01
The Center for Therapeutic Targeting of EWS-oncoproteins
- Amount
- $12.5M
- Period
- 2018-09-10 → 2024-06-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #5R35CA210030-07
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
- Amount
- $1.0M
- Period
- 2016-08-09 → 2023-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #5R35CA210030-06
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
- Amount
- $1.0M
- Period
- 2016-08-09 → 2023-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #5P50CA206963-06
Targeting SYK Kinase in AML
- Amount
- $21K
- Period
- 2017-09-19 → 2023-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #5R35CA210030-05
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
- Amount
- $1.1M
- Period
- 2016-08-09 → 2023-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #5R35CA210030-04
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
- Amount
- $1.0M
- Period
- 2016-08-09 → 2023-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #5R35CA210030-03
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
- Amount
- $1.0M
- Period
- 2016-08-09 → 2023-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #5R35CA210030-02
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
- Amount
- $1.0M
- Period
- 2016-08-09 → 2023-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #1R35CA210030-01
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
- Amount
- $1.0M
- Period
- 2016-08-09 → 2023-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #5R01CA204915-05
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics
- Amount
- $397K
- Period
- 2017-01-01 → 2022-06-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #5R01CA204915-04
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics
- Amount
- $480K
- Period
- 2017-01-01 → 2022-06-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #5R01CA204915-03
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics
- Amount
- $385K
- Period
- 2017-01-01 → 2021-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #3R01CA204915-03S1
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics
- Amount
- $120K
- Period
- 2017-01-01 → 2021-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #3R01CA204915-02S1
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics
- Amount
- $229K
- Period
- 2017-01-01 → 2021-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #5R01CA204915-02
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics
- Amount
- $397K
- Period
- 2017-01-01 → 2021-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #1R01CA204915-01A1
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics
- Amount
- $397K
- Period
- 2017-01-01 → 2021-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #5R01NS088355-05
Targeting BET-bromodomains in neuroblastoma
- Amount
- $641K
- Period
- 2015-05-15 → 2021-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
NIH #3R01CA204915-02S2
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics
- Amount
- $40K
- Period
- 2017-01-01 → 2020-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #5R01NS088355-04
Targeting BET-bromodomains in neuroblastoma
- Amount
- $651K
- Period
- 2015-05-15 → 2020-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
NIH #5R01NS088355-03
Targeting BET-bromodomains in neuroblastoma
- Amount
- $675K
- Period
- 2015-05-15 → 2020-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
NIH #5R01NS088355-02
Targeting BET-bromodomains in neuroblastoma
- Amount
- $669K
- Period
- 2015-05-15 → 2020-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
NIH #1R01NS088355-01A1
Targeting BET-bromodomains in neuroblastoma
- Amount
- $699K
- Period
- 2015-05-15 → 2020-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
NIH #2R01CA140292-06
Validating Syk as a Target for AML Therapy
- Amount
- $388K
- Period
- 2009-07-07 → 2019-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #5P50CA206963-02
Targeting SYK Kinase in AML
- Amount
- $348K
- Period
- — → 2019-03-31
- PIs
- 1
- Est. capacity / PI
- ~5 students
Awarded at BRIGHAM AND WOMEN'S HOSPITAL
NIH #3R01CA204915-01A1S1
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics
- Amount
- $229K
- Period
- 2017-01-01 → 2018-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #5R01CA140292-07
Validating Syk as a Target for AML Therapy
- Amount
- $388K
- Period
- 2009-07-07 → 2016-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #5R01CA140292-05
Validating Syk as a Target for AML Therapy
- Amount
- $331K
- Period
- 2009-07-07 → 2014-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #5R03DA034596-02
Targeting the ETS Transcription Factor Rearrangement EWS/FLI in Ewing's Sarcoma
- Amount
- $42K
- Period
- 2012-05-01 → 2014-04-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #5R01CA140292-04
Validating Syk as a Target for AML Therapy
- Amount
- $352K
- Period
- 2009-07-07 → 2014-04-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at DANA-FARBER CANCER INST
NIH #7P50CA206963-03
Targeting SYK Kinase in AML
- Amount
- $90K
- Period
- — → —
- PIs
- 1
- Est. capacity / PI
- ~1 students
Awarded at DANA-FARBER CANCER INST
NIH #1P50CA206963-01A1
Targeting SYK Kinase in AML
- Amount
- $334K
- Period
- — → —
- PIs
- 1
- Est. capacity / PI
- ~5 students
Awarded at BRIGHAM AND WOMEN'S HOSPITAL